Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy

Does Nektar Therapeutics (NKTR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Dec 8, 2025

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO , Dec. 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 18,310 shares of its common stock to two newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Nektar, pursuant to Nasdaq Listing Rule 5635(c)(4).

PRNewsWire • Dec 5, 2025

Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 64.5% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Dec 1, 2025

Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect?

The consensus price target hints at a 62.8% upside potential for Nektar (NKTR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Nov 13, 2025

Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout

Nektar Therapeutics has pivoted from oncology to focus on autoimmune and inflammatory diseases, with Rezpegaldesleukin (Rezpeg) as its lead asset. NKTR's value now centers on Treg biology, advancing Rezpeg and NKTR-0165, and leveraging legacy oncology partnerships for monetization. Key catalysts are upcoming Q1 2026 readouts: Phase 2b alopecia areata data and 36-week atopic dermatitis data for Rezpeg.

Seeking Alpha • Nov 12, 2025

Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets

Nektar Therapeutics (NKTR) develops novel immunomodulatory drugs targeting autoimmune diseases and oncology, leveraging its expertise in immune system regulation. Recent Phase 2 results for Atopic Dermatitis met endpoints, validating NKTR's approach and boosting confidence in its platform's clinical potential. NKTR's pipeline includes rezpegaldesleukin for other indications, and NKTR-255 for cancer, addressing significant unmet medical needs.

Seeking Alpha • Nov 12, 2025

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Extended dosing with rezpegaldesleukin q2w supports 24-week induction period for planned Phase 3 studies with improvement across major efficacy endpoints from Week 16 to 24, including EASI-75, EASI-90, and vIGA-AD Data from long-term maintenance portion of REZOLVE-AD with 52 weeks of treatment expected in Q1 2026 from REZOLVE-AD study Top-line Phase 2b data for rezpegaldesleukin in alopecia areata to be reported in December 2025 SAN FRANCISCO , Nov. 8, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking oral abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting. Rezpegaldesleukin is a first-in-class IL-2 pathway agonist and regulatory T-cell (Treg) biologic currently being studied in a Phase 2b study in moderate-to-severe atopic dermatitis (REZOLVE-AD) and a separate Phase 2b study in patients with severe-to-very-severe alopecia areata (REZOLVE-AA).

PRNewsWire • Nov 8, 2025

Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript

Nektar Therapeutics ( NKTR ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Vivian Wu Howard W. Robin - CEO, President & Director Jonathan Zalevsky - Senior VP and Chief Research & Development Officer Sandra Gardiner - CFO and Principal Financial & Accounting Officer Mary Tagliaferri - Chief Medical Officer Conference Call Participants Julian Harrison - BTIG, LLC, Research Division Cheng Li - Oppenheimer & Co. Inc., Research Division Cha Cha Yang - Jefferies LLC, Research Division Mayank Mamtani - B.

Seeking Alpha • Nov 7, 2025

Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.

Zacks Investment Research • Nov 7, 2025

Nektar Therapeutics Reports Third Quarter 2025 Financial Results

SAN FRANCISCO , Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2025. Cash and investments in marketable securities on September 30, 2025 were $270.2 million as compared to $269.1 million on December 31, 2024.

PRNewsWire • Nov 6, 2025